As the global biopharmaceutical industry undergoes rapid transformation, Southeast Asia-with its burgeoning market potential and demand for industrial upgrades-has become a new hotspot for international pharmaceutical competition and collaboration.
As a major annual event for the pharmaceutical industry in Southeast Asia, CPHI South East Asia 2025 is not only a platform for showcasing technological achievements but also a bridge for deep integration of pharmaceutical resources. Tailin, a leading enterprise in China’s pharmaceutical equipment sector, participated with cutting-edge solutions, signaling a strong step toward deeper synergy with the Southeast Asian pharmaceutical industry.
At this exhibition, Tailin showcased key solutions spanning the entire biopharmaceutical production process, forming a multi-dimensional and systematic product matrix. From microbial detection-such as intelligent Sterility Testing Systems and Microbial Limit Testing Systems-to microbial control with Aseptic Isolators, Glove Integrity Testers, and Vaporized Hydrogen Peroxide Sterilizers, and then to microbial validation tools such as Biological And Chemical Indicators, the company has built a comprehensive, efficient, and closed-loop microbial detection and control system. TOC Analyzers and fully automated Filter Integrity Testers serve as critical tools to ensure the compliance of water systems and filtration processes. Products such as Online Microbial Monitoring System and Container Closure Integrity Testers further strengthen capabilities in microbial monitoring and product safety assurance.
The exhibited products cover core areas including aseptic production, leak testing, microbial detection, and water quality safety testing. These offerings respond precisely to the real needs of the Southeast Asian market in terms of GMP compliance upgrades and production capacity optimization, demonstrating Tailin’s professional strength and comprehensive service capabilities in helping customers improve production efficiency and quality control.
At the exhibition, Tailin’s booth attracted executives from pharmaceutical companies, research institution experts, and industry decision-makers from several Southeast Asian countries including Malaysia, Thailand, Singapore, and Indonesia. Through intensive technical communication and demand alignment, Tailin not only gained clearer insight into the pressing needs of the Southeast Asian pharmaceutical industry in areas such as compliance system construction and aseptic process upgrades, but also laid a strong foundation for future customized solutions and project implementation, reinforcing a solid basis for mutual cooperation and win-win outcomes.
Tailin’s participation in CPHI SEA 2025 marks a key milestone in advancing its globalization strategy. As a pioneering enterprise driving China’s pharmaceutical equipment industry onto the international stage, Tailin is building a comprehensive and multi-layered cooperation network in the Southeast Asian market through technical collaboration, capacity coordination, and ecosystem co-construction. In the future, the company will continue to be driven by technological innovation and guided by customer value, deepening cooperation with global partners, contributing Chinese strength to the compliant, intelligent, and sustainable development of the international biopharmaceutical industry, and writing a new chapter in the restructuring of the global pharmaceutical supply chain.
More info: CPHI South East Asia 2025 | YouTube
